China Medical System Wins NMPA Approval to Begin Clinical Trials for CMS-D017
I'm PortAI, I can summarize articles.
China Medical System Holdings Limited has received approval from the National Medical Products Administration (NMPA) to begin clinical trials for its innovative drug CMS-D017, aimed at treating complement-mediated kidney disease. The trials will assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants. The company plans to initiate these trials and hopes to launch the product following successful development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments